Why the study?
Does rosiglitazone improve vascular tone or permeability in obese, insulin-resistant, nondiabetic subjects?
Does rosiglitazone improve vascular tone or permeability in obese, insulin-resistant, nondiabetic subjects?
Rosiglitazone-induced fluid retention in insulin-resistant subjects is not caused by changes in vascular permeability or NO-dependent vasodilatation, but correlates with improvements in insulin sensitivity.
No takes yet. Share an insight, caveat, or question.
Rosiglitazone-induced fluid retention occurs without changes in permeability or vasodilation; extends mechanistic understanding to insulin-sensitization effects in insulin-resistant subjects.
Rennings et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: